Rawls Scott M, Schroeder Joseph A, Ding Zhe, Rodriguez Tony, Zaveri Nurulain
Department of Pharmaceutical Sciences, Temple University School of Pharmacy and Center for Substance Abuse Research, 3307 North Broad Street, Philadelphia, PA 19140, USA.
Neuropeptides. 2007 Aug;41(4):239-47. doi: 10.1016/j.npep.2007.03.001. Epub 2007 May 23.
The present study used the endpoint of hypothermia to investigate cannabinoid and nociceptin/orphanin FQ (N/OFQ) interactions in conscious animals. Prior work has established that cannabinoids produce hypothermia by activating central cannabinoid CB(1) receptors. The administration of N/OFQ into the brain also causes significant hypothermia. Those data suggest a link between cannabinoid CB(1) receptors and N/OFQ peptide (NOP) receptors in the production of hypothermia. Therefore, we determined if NOP receptor activation is required for cannabinoid-evoked hypothermia and if cannabinoid CB(1) receptor activation is necessary for N/OFQ-induced hypothermia. In actual experiments, a cannabinoid agonist, WIN 55212-2 (2.5, 5, and 10 mg/kg, i.p.), caused significant hypothermia in male Sprague-Dawley rats (200-225 g). A NOP receptor antagonist, JTC-801 (1 mg/kg, i.p.), did not affect body temperature. For combined administration, JTC-801 (1 mg/kg, i.p.) blocked a significant proportion of the hypothermia caused by each dose of WIN 55212-2 (2.5, 5, and 10 mg/kg, i.p.). JTC-801 (1 mg/kg, i.p.) also blocked the hypothermia caused by another cannabinoid agonist, CP-55, 940 (1 mg/kg, i.p.). In separate experiments, the direct administration of N/OFQ (9 microg/rat, i.c.v.) into the brain produced significant hypothermia. The hypothermic effect of N/OFQ was blocked by JTC-801 (1 mg/kg, i.p.) but not by a selective cannabinoid CB(1) antagonist, SR 141716A (5 mg/kg, i.m.). The finding that a NOP receptor antagonist abolishes a significant percentage of cannabinoid-induced hypothermia suggests that NOP receptor activation is required for cannabinoids to produce hypothermia. This interaction, quantitated in the present study, is the first evidence that NOP receptors mediate a cannabinoid-induced effect in conscious animals.
本研究采用体温过低这一终点指标,来探究大麻素与痛敏肽/孤啡肽FQ(N/OFQ)在清醒动物体内的相互作用。先前的研究已证实,大麻素通过激活中枢大麻素CB(1)受体来降低体温。向脑内注射N/OFQ也会导致显著的体温过低。这些数据表明,在体温过低的产生过程中,大麻素CB(1)受体与N/OFQ肽(NOP)受体之间存在联系。因此,我们确定了大麻素诱发的体温过低是否需要NOP受体激活,以及N/OFQ诱导的体温过低是否需要大麻素CB(1)受体激活。在实际实验中,一种大麻素激动剂WIN 55212-2(2.5、5和10毫克/千克,腹腔注射)在雄性Sprague-Dawley大鼠(200-225克)中引起了显著的体温过低。一种NOP受体拮抗剂JTC-801(1毫克/千克,腹腔注射)对体温没有影响。对于联合给药,JTC-801(1毫克/千克,腹腔注射)阻断了各剂量WIN 55212-2(2.5、5和10毫克/千克,腹腔注射)所引起的大部分体温过低。JTC-801(1毫克/千克,腹腔注射)也阻断了另一种大麻素激动剂CP-55,940(1毫克/千克,腹腔注射)所引起的体温过低。在单独的实验中,向脑内直接注射N/OFQ(9微克/只大鼠,脑室内注射)产生了显著的体温过低。N/OFQ的降温作用被JTC-801(1毫克/千克,腹腔注射)阻断,但未被选择性大麻素CB(1)拮抗剂SR 141716A(5毫克/千克,肌肉注射)阻断。NOP受体拮抗剂消除了相当比例的大麻素诱导的体温过低这一发现表明,大麻素产生体温过低需要NOP受体激活。本研究中定量的这种相互作用,是NOP受体介导清醒动物体内大麻素诱导效应的首个证据。